Redhill Other Current Assets vs Preferred Stock Total Equity Analysis
| RDHL Stock | USD 0.46 0.01 2.22% |
Redhill Biopharma financial indicator trend analysis is much more than just breaking down Redhill Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Redhill Biopharma is a good investment. Please check the relationship between Redhill Biopharma Other Current Assets and its Preferred Stock Total Equity accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.
Other Current Assets vs Preferred Stock Total Equity
Other Current Assets vs Preferred Stock Total Equity Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Redhill Biopharma Other Current Assets account and Preferred Stock Total Equity. At this time, the significance of the direction appears to have very week relationship.
The correlation between Redhill Biopharma's Other Current Assets and Preferred Stock Total Equity is 0.23. Overlapping area represents the amount of variation of Other Current Assets that can explain the historical movement of Preferred Stock Total Equity in the same time period over historical financial statements of Redhill Biopharma, assuming nothing else is changed. The correlation between historical values of Redhill Biopharma's Other Current Assets and Preferred Stock Total Equity is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Assets of Redhill Biopharma are associated (or correlated) with its Preferred Stock Total Equity. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Preferred Stock Total Equity has no effect on the direction of Other Current Assets i.e., Redhill Biopharma's Other Current Assets and Preferred Stock Total Equity go up and down completely randomly.
Correlation Coefficient | 0.23 |
| Relationship Direction | Positive |
| Relationship Strength | Very Weak |
Other Current Assets
Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.Preferred Stock Total Equity
Most indicators from Redhill Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Redhill Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.The value of Selling General Administrative is expected to slide to about 18.4 M. The value of Issuance Of Capital Stock is estimated to slide to about 13.3 M
Redhill Biopharma fundamental ratios Correlations
Click cells to compare fundamentals
Redhill Biopharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Redhill Biopharma fundamental ratios Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 74.1M | 180.2M | 181.2M | 158.9M | 23.0M | 21.9M | |
| Other Current Liab | 107K | 18.3M | 30.9M | 77.0M | 15.2M | 12.9M | |
| Total Current Liabilities | 10.6M | 73.2M | 81.5M | 197.5M | 19.2M | 33.1M | |
| Other Liab | 844K | 500K | 7.9M | 4.6M | 5.3M | 2.8M | |
| Accounts Payable | 4.2M | 11.6M | 11.7M | 4.2M | 3.3M | 4.2M | |
| Cash | 29.0M | 29.3M | 29.5M | 20.0M | 6.4M | 6.0M | |
| Common Stock Shares Outstanding | 742.3K | 910.7K | 1.2M | 1.5M | 6.5M | 6.8M | |
| Short Term Investments | 29.8M | 24.2M | 18.8M | 498K | 8.5M | 0.0 | |
| Other Current Assets | 2.2M | 5.5M | 3.8M | 19.6M | 797.0K | 757.2K | |
| Total Liab | 14.1M | 166.4M | 172.3M | 207.3M | 21.0M | 19.9M | |
| Intangible Assets | 16.9M | 87.9M | 71.6M | 65.6M | 5.6M | 5.3M | |
| Common Stock | 962K | 1.1M | 1.5M | 2.8M | 21.4M | 22.5M | |
| Property Plant Equipment | 163K | 3.8M | 5.7M | 4.2M | 4.9M | 5.1M | |
| Total Stockholder Equity | 60.0M | 13.9M | 8.9M | (48.4M) | 2.1M | 2.0M | |
| Property Plant And Equipment Net | 3.8M | 5.7M | 4.2M | 7.2M | 1.2M | 2.0M | |
| Net Debt | (25.2M) | 57.6M | 58.3M | 102.7M | (5.2M) | (4.9M) | |
| Retained Earnings | (208.4M) | (280.3M) | (367.9M) | (433.9M) | (407.7M) | (387.4M) | |
| Non Current Assets Total | 20.9M | 109.7M | 92.0M | 73.0M | 6.9M | 6.6M | |
| Non Currrent Assets Other | (20.7M) | 16.2M | 16.2M | 150K | 147K | 139.7K | |
| Cash And Short Term Investments | 47.9M | 29.8M | 38.0M | 20.0M | 6.4M | 6.0M | |
| Net Receivables | 1.2M | 28.7M | 32.5M | 35.4M | 3.3M | 3.1M | |
| Common Stock Total Equity | 575K | 767K | 962K | 1.1M | 1.2M | 1.3M | |
| Liabilities And Stockholders Equity | 74.1M | 180.2M | 181.2M | 158.9M | 23.0M | 21.9M | |
| Non Current Liabilities Total | 3.5M | 93.1M | 90.8M | 9.8M | 1.7M | 1.6M | |
| Inventory | 1.9M | 6.5M | 14.8M | 11.0M | 5.7M | 6.0M | |
| Other Stockholder Equity | 267.4M | 293.1M | 375.2M | 382.6M | 388.4M | 217.0M | |
| Property Plant And Equipment Gross | 3.8M | 5.7M | 5.0M | 8.3M | 2.4M | 2.2M | |
| Total Current Assets | 53.2M | 70.5M | 89.2M | 85.9M | 16.1M | 15.3M | |
| Net Tangible Assets | 45.9M | 43.1M | (74.0M) | (62.8M) | (56.5M) | (53.7M) | |
| Net Invested Capital | 60.0M | 95.3M | 92.5M | 66.8M | 2.1M | 2.0M | |
| Net Working Capital | 42.6M | (2.7M) | 7.7M | (111.6M) | (3.1M) | (2.9M) | |
| Capital Stock | 962K | 1.1M | 1.5M | 2.8M | 21.4M | 22.5M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Redhill Biopharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Redhill Biopharma's short interest history, or implied volatility extrapolated from Redhill Biopharma options trading.
Currently Active Assets on Macroaxis
When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Redhill Stock analysis
When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators |
Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 4 | Revenue Per Share 1.008 | Quarterly Revenue Growth (0.96) | Return On Assets (0.16) | Return On Equity (8.84) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.